Fenharmane

Fenharmane
Clinical data
Other namesFenharman; Phenharman; Phenharmane; Fenoharman; Fenoharmane; Phenoharman; Phenoharmane; 1-Benzyl-1,2,3,4-tetrahydronorharmane; Benzyltetrahydronorharman
Drug classSedative; Tranquilizer; Reserpine-like agent
Identifiers
  • 1-benzyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H18N2
Molar mass262.356 g·mol−1
3D model (JSmol)
  • C1CNC(C2=C1C3=CC=CC=C3N2)CC4=CC=CC=C4
  • InChI=1S/C18H18N2/c1-2-6-13(7-3-1)12-17-18-15(10-11-19-17)14-8-4-5-9-16(14)20-18/h1-9,17,19-20H,10-12H2
  • Key:LHVNPTMRAQQPID-UHFFFAOYSA-N

Fenharmane (INNTooltip International Nonproprietary Name), also known as 1-benzyl-1,2,3,4-tetrahydronorharmane, is a sedative and tranquilizer of the β-carboline family.[1][2] It has been said to have actions similar to those of reserpine, a monoamine-depleting agent.[3][4][5][6] The drug has been reported to induce symptoms of depression analogously to reserpine.[7][8] Fenharmane was developed in Czechoslovakia in the late 1950s.[3][2][9]

See also

References

  1. ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 144–145. ISBN 978-1-4757-2085-3.
  2. ^ a b Švestka J (2000). "S31.03 The history of czech psychopharmacology and psychopharmacotherapy of affective and schizophrenic disorders" (PDF). European Psychiatry. 15 (S2): 277s. doi:10.1016/S0924-9338(00)94205-6. ISSN 0924-9338. Retrieved 30 May 2025.
  3. ^ a b Dlabac A, Macek K, Vanecek M, Trcka V (April 1959). "Reserpinový úćinek fenoharmanu" [Reserpine-like action of phenoharmane]. Československá fysiologie (in Czech). 8 (3): 177–178. PMID 13671512.
  4. ^ Trcka V, Dlabac A, Vanecek M (1961). "[The reserpine-like action of 1-benzyl-1,2,3,4-tetrahydronorharmane (fenoharman)]". Journal de Physiologie (in French). 53: 488–489. PMID 13777950.
  5. ^ Nahunek K, Rodova A, Hosak L, Jaros M, Hadlik J (July 1962). "[Nialamid and its combinations with reserpine-like substances (fenoharman, reserpine) in the therapy of endogenous depressions]". Deutsches Medizinisches Journal (in German). 13: 424–425. PMID 14477998.
  6. ^ Rysanek K, Vitek V, Spankova H (1962). "[Comparative effects of Reserpine and Fenoharman on the absorption and liberation of serotonin in vivo and in vitro]". Activitas Nervosa Superior (in Czech). 4: 220–221. PMID 14495652.
  7. ^ Bermanzohn PC, Siris SG (1992). "Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia". Comprehensive Psychiatry. 33 (4): 221–232. doi:10.1016/0010-440x(92)90045-r. PMID 1353715.
  8. ^ Tesařová O (1972). "Experimental Depression Caused by Apomorphine and Phenoharmane". Pharmacopsychiatry. 5 (1): 13–19. doi:10.1055/s-0028-1094329. ISSN 0176-3679. Retrieved 30 May 2025.
  9. ^ Vinar O (November 1960). "[Use of Fenoharman, a new Czechoslovak preparation, in psychiatry (preliminary communication)]". Časopis lékařů českých (in Czech). 99: 1422–1424. PMID 13781443.
Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.